• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Fresh Tracks Therapeutics Inc.

    5/8/24 4:01:47 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FRTX alert in real time by email
    SC 13D 1 ea0205585-13dexplor_fresh.htm SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION,
    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. N/A)*

     

    Fresh Tracks Therapeutics, Inc.
    (Name of Issuer)

     

    Common Stock, par value $0.01
    (Title of Class of Securities)

     

    10802T204
    (CUSIP Number)

     

    Stephen Gustin

    Exploration Capital

    250 East 200 South, Floor 16

    Salt Lake City, UT 84111

    212.220.4444

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    May 1, 2024
    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     CUSIP No.         10802T204

     

    (1)

    Name of Reporting Person

     

    Exploration Capital, LLC

     

    (2) Check the Appropriate Box if a Member of a Group
      (a) ☐     (b) ☐
       
    (3) SEC Use Only
       
    (4)

    Source of Funds

     

    AF

     

    (5)

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

    (6)

    Citizenship or Place of Organization

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    (7)

    Sole Voting Power

     

    None 

     

    (8)

    Shared Voting Power

     

    1,226,024

    (9)

    Sole Dispositive Power

     

    None 

     

    (10)

    Shared Dispositive Power

     

    1,226,024

    (11)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,226,024

       
       
    (12)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

       
       
    (13)

    Percent of Class Represented by Amount in Row (9)

     

    20.5%

       
    (14)

    Type of Reporting Person

     

    OO

     

    2

     

     

     CUSIP No.         10802T204

     

    (1)

    Name of Reporting Person

     

    Stephen L. Gustin

     

    (2) Check the Appropriate Box if a Member of a Group
      (a) ☐     (b) ☐
       
    (3) SEC Use Only
       
    (4)

    Source of Funds

     

    PF

     

    (5)

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

    (6)

    Citizenship or Place of Organization

     

    United States

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    (7)

    Sole Voting Power

     

    47,000 

     

    (8)

    Shared Voting Power

     

    1,273,024

     

    (9)

    Sole Dispositive Power

     

    47,000 

     

    (10)

    Shared Dispositive Power

     

    1,273,024

     

    (11)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,273,024

       
       
    (12)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

       
       
    (13)

    Percent of Class Represented by Amount in Row (9)

     

    21.3%

       
    (14)

    Type of Reporting Person

     

    IN

      

    3

     

     

    This Statement on Schedule 13D is filed with respect to 1,273,024 shares of the Common Stock, par value $0.01 per share, of Fresh Tracks Therapeutics, Inc. (“FRTX” or the “Issuer”) held by Exploration Capital, LLC (“X-Cap”) and by Stephen L. Gustin (“Stephen Gustin”). X-Cap and Stephen Gustin previously filed a Statement on Schedule 13G with respect to the ownership of Common Stock, par value $0.01 per share (the “Shares”) of FRTX. X-Cap and Stephen Gustin are required to file this Statement on Schedule 13D as a result of acquiring additional Shares of FRTX such that aggregate beneficial ownership exceeds 20%.

     

    ITEM 1. SECURITY AND ISSUER.

     

    This statement relates to the Common Stock, par value $0.01 per share, of Fresh Tracks Therapeutics, Inc., a Delaware corporation. The address of the principal executive offices of the Issuer is 2000 Central Avenue, Boulder, CO 80301.

     

    ITEM 2. IDENTITY AND BACKGROUND.

     

    (a) Name:

     

    This statement is filed by Exploration Capital, LLC and Stephen L. Gustin. Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    (b) Residence or business address:

     

    The address of the principal office of each Reporting Person is 250 East 200 South, Floor 16, Salt Lake City, UT 84111.

     

    (c) Present principal occupation or employment:

     

    X-Cap’s principal business is investment management. Stephen Gustin’s principal business is serving as Managing Partner of X-Cap.

     

    (d) Criminal convictions:

     

    No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) Civil proceedings:

     

    No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) Citizenship / State of incorporation/organization:

     

    X-Cap is organized under the laws of the State of Delaware. Stephen Gustin is a citizen of the United States of America.

     

    4

     

     

    ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

     

    Funds for the purchase of the Shares by X-Cap were derived from the subscription proceeds from investors and the capital appreciation thereon and margin account borrowings made in the ordinary course of business. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of the margin loans, which may exist from time to time. Since other securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the Shares reported herein.

     

    Shares held individually by Stephen Gustin were purchased with personal funds.

     

    A total of approximately $1,133,808 was paid (excluding brokerage commissions) to acquire the 1,273,024 shares reported herein.

     

    ITEM 4. PURPOSE OF TRANSACTION.

     

    The Reporting Persons acquired the Shares for investment purposes. The Reporting Persons may determine to purchase additional Shares in the open market or otherwise, depending upon price, market conditions, availability of funds, evaluation of alternative investments and other factors. While none of the Reporting Persons have any present plans to sell any Shares, one or more of them could determine, based upon the same set of factors listed above with respect to purchases, to sell some or all of the Shares. Except as set forth above, the Reporting Persons have no intention to effect any of the transactions specified in Item 4 of Schedule 13D.

     

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

     

    (a) Amount and percentage owned:

     

    See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Shares and percentages of the Shares beneficially owned by each of the Reporting Persons.

     

    The percentages used herein are calculated based upon 5,973,306 shares of common stock outstanding as of March 15, 2024, which is the total number of Shares outstanding as reported in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2024.

     

    (b) Sole or shared power:

     

    See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Common Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

     

    (c) Transactions in the securities of the issuer during the past 60 days:

     

    Schedule A annexed hereto lists all transactions in securities of the Issuer by X-Cap during the past 60 days. All of the transactions were in the open market. No securities were purchased individually by Stephen Gustin in the past 60 days.

     

    (d) Others with power to direct receipt of dividends/sale proceeds:

     

    None

     

    (e) Date ceased to be beneficial owner of more than five percent:

     

    Not applicable

     

    ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

     

    None

     

    ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

     

    None

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

      Dated: 05/08/2024
           
      Exploration Capital, LLC
       
      Signature.  /s/ Stephen L. Gustin
        Stephen L. Gustin
        Managing  Partner

     

      Stephen L. Gustin 
       
      Signature.  /s/ Stephen L. Gustin
        Stephen L.  Gustin 

     

    6

     

      

    CUSIP No. 10802T204

     

    Schedule A

    Transactions in the Securities of the Issuer During the Past Sixty Days

     

    Trade Date  Shares   Price ($)   Buy/Sell 
    03/11/24   5,703    0.91    Buy 
    03/12/24   1,500    0.91    Buy 
    03/13/24   9,126    0.92    Buy 
    03/19/24   10    0.90    Buy 
    03/20/24   287    0.91    Buy 
    03/27/24   51,634    0.90    Buy 
    03/28/24   2,586    0.90    Buy 
    04/01/24   354    0.89    Buy 
    04/03/24   12,928    0.91    Buy 
    04/04/24   3,400    0.91    Buy 
    04/05/24   1,050    0.91    Buy 
    04/09/24   2,188    0.88    Buy 
    04/10/24   1,000    0.88    Buy 
    04/19/24   4,277    0.91    Buy 
    04/22/24   16,908    0.90    Buy 
    04/23/24   343    0.91    Buy 
    05/01/24   162,351    0.92    Buy 
    05/02/24   2,222    0.91    Buy 
    05/04/24   324    0.91    Buy 
    05/06/24   320    0.89    Buy 

     

     

     

     

     

    Get the next $FRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FRTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Fresh Tracks Therapeutics Inc.

      SC 13D - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      5/8/24 4:01:47 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fresh Tracks Therapeutics Inc. (Amendment)

      SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      1/17/24 8:37:18 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fresh Tracks Therapeutics Inc. (Amendment)

      SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      2/13/23 5:24:48 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Exploration Capital, Llc bought $381,170 worth of shares (405,500 units at $0.94) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      6/11/24 9:37:53 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $9,580 worth of shares (10,434 units at $0.92) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/31/24 5:29:19 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $20,821 worth of shares (22,889 units at $0.91) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/23/24 5:29:14 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Exploration Capital, Llc bought $381,170 worth of shares (405,500 units at $0.94) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      6/11/24 9:37:53 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $9,580 worth of shares (10,434 units at $0.92) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/31/24 5:29:19 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $20,821 worth of shares (22,889 units at $0.91) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/23/24 5:29:14 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market

      BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today an update on its previously announced, planned dissolution and its process for distributing cash to its stockholders. Fresh Tracks plans on filing a Certificate of Dissolution with the Delaware Secretary of State, with dissolution effective February 28, 2025. As previously disclosed, on January 15, 2025, the Court of Chancery of the State of Delaware appointed Albert N. Marchio II as the custodian of the Company (the "Custodian"). In connection with the dissolution, the Custodian has authorized an initial distribution of $0.96 per share to holders, as of

      2/25/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • /C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./

      In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution

      BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • /C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./

      In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution

      BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company

      BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma

      6/17/24 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Fresh Tracks Therapeutics Inc.

      15-12G - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/18/24 5:05:32 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Fresh Tracks Therapeutics Inc.

      10-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/15/24 4:09:01 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/7/24 8:44:19 AM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Financials

    Live finance-specific insights

    See more
    • Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value Strengthened balance sheet with aggregate net proceeds of $6.6 million raised under an ATM program in March 2023 BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today

      5/10/23 4:01:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

      Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Continuing to evaluate strategic options to further develop FRTX-02 and maximize shareholder value Raised aggregate net proceeds of $6.6 million under ATM program in March 2023 BOULDER, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription the

      3/30/23 4:01:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care